MANTECH Publications

Amruta: A Journal on Prasuti Tantra, Stree and Bal Rog
Volume 2, Issue 1, January-June, 2023

Adenomyosis in Women with Inflammatory Uterine Diseases: Pathophysiology, Clinical Features, Diagnosis, and Treatment Options

Prof. Mahesh Vyas[1], Gourav Rai[2]

Professor[1], Student[2]

Department of Stree Rog

Swami Kalyan Dev Government Ayurvedic College

Corresponding Author's Email: - *gouravraiccaptain@gmail.com*

Abstract

Adenomyosis is a gynecological disorder that affects women of reproductive age. It is characterized by the presence of endometrial tissue within the myometrium, leading to enlargement and thickening of the uterus. Inflammatory diseases of the uterus such as endometritis, chronic cervicitis, and pelvic inflammatory disease (PID) are known to be associated with adenomyosis. The aim of this paper is to review the features of the course of adenomyosis in women with inflammatory diseases of the uterus. The paper discusses the pathophysiology, clinical features, diagnosis, and treatment of adenomyosis in women with inflammatory diseases of the uterus.

Keywords: *Adenomyosis, inflammatory diseases, endometritis, chronic cervicitis, pelvic inflammatory disease, pathophysiology, clinical features, diagnosis, treatment.*

INTRODUCTION

Adenomyosis is a common gynecological disorder that affects women of reproductive age. It is characterized by the presence of endometrial tissue within the myometrium, leading to enlargement and thickening of the uterus. Adenomyosis can lead to a range of symptoms, including dysmenorrhea, menorrhagia, dyspareunia, and infertility. Inflammatory diseases of the uterus such as endometritis, chronic cervicitis, and PID are known to be

associated with adenomyosis. Chronic inflammation can promote the growth of endometrial tissue within the myometrium, leading to the development of adenomyosis. The aim of this paper is to review the features of the course of adenomyosis in women with inflammatory diseases of the uterus.

PATHOPHYSIOLOGY

The pathophysiology of adenomyosis involves a disruption of the barrier between the endometrium and the myometrium, which allows the endometrial tissue to invade the myometrium. Normally, the endometrial lining of the uterus undergoes cyclic changes in response to the menstrual cycle. During menstruation, the endometrium sheds and is replaced by a new layer of tissue. However, in some women, the endometrial tissue grows into the underlying myometrium, leading to the development of adenomyosis.

The exact cause of this disruption is not fully understood, but it is believed to be related to a combination of genetic, hormonal, and environmental factors. One theory suggests that adenomyosis develops as a result of a defect in the junctional zone, a transitional layer between the endometrium and the myometrium. This defect allows the endometrial tissue to invade the myometrium and proliferate, leading to the characteristic enlargement and thickening of the uterus seen in adenomyosis.

Another theory suggests that chronic inflammation plays a role in the development of adenomyosis. Inflammatory diseases of the uterus such as endometritis, chronic cervicitis, and pelvic inflammatory disease (PID) can lead to the release of cytokines and growth factors that promote the growth of endometrial tissue within the myometrium. Chronic inflammation can also lead to the development of fibrosis and scarring within the myometrium, further promoting the growth of endometrial tissue.

Hormonal factors may also play a role in the pathophysiology of adenomyosis. Estrogen is known to stimulate the growth of endometrial tissue, and the excessive accumulation of estrogen within the uterus may contribute to the development of adenomyosis. In addition, progesterone resistance has been implicated in the development of adenomyosis, as it can lead to the abnormal proliferation of endometrial tissue.

The pathophysiology of adenomyosis is complex and multifactorial, involving a combination of genetic, hormonal, and environmental factors. Inflammatory diseases of the uterus are known to be associated with adenomyosis, and chronic inflammation is believed to promote the growth of endometrial tissue within the myometrium. Further research is needed to fully understand the mechanisms underlying the development of adenomyosis and its relationship to inflammatory diseases of the uterus.

CLINICAL FEATURES

The clinical presentation of adenomyosis can be variable, and some women may have no symptoms at all. However, in women with adenomyosis and coexisting inflammatory diseases of the uterus, symptoms may be more severe and difficult to manage. The clinical features of adenomyosis can be divided into three categories: menstrual symptoms, non-menstrual symptoms, and complications.

Menstrual symptoms are the most common clinical features of adenomyosis. Women with adenomyosis may experience heavy or prolonged menstrual bleeding, dysmenorrhea (painful periods), and irregular bleeding. The severity of menstrual symptoms can vary depending on the extent and location of the adenomyotic lesions within the uterus. Women with more diffuse adenomyosis may experience more severe menstrual symptoms than those with focal adenomyosis.

Non-menstrual symptoms of adenomyosis can include chronic pelvic pain, dyspareunia (painful intercourse), and dyschezia (painful bowel movements). These symptoms may occur throughout the menstrual cycle and can be difficult to manage. Chronic pelvic pain associated with adenomyosis may be due to the inflammation and fibrosis within the myometrium, which can lead to nerve irritation and sensitization.

Complications of adenomyosis can include anemia due to heavy menstrual bleeding, infertility, and preterm labor. Adenomyosis can interfere with the normal contractions of the uterus, which can lead to difficulty conceiving or maintaining a pregnancy. Women with adenomyosis may also be at increased risk of preterm labor due to the disruption of the uterine environment.

In women with coexisting inflammatory diseases of the uterus, such as endometritis or PID, the clinical features of

adenomyosis may be more severe. Chronic inflammation can exacerbate the symptoms of adenomyosis and may increase the risk of complications such as anemia and infertility.

The clinical features of adenomyosis can vary widely and may include menstrual symptoms, non-menstrual symptoms, and complications. Women with coexisting inflammatory diseases of the uterus may experience more severe symptoms and an increased risk of complications. Effective management of adenomyosis requires a thorough understanding of the clinical features and underlying pathophysiology of the condition.

DIAGNOSIS

The diagnosis of adenomyosis can be challenging, as the clinical presentation of the condition can be similar to other gynecologic conditions such as uterine fibroids, endometriosis, or pelvic inflammatory disease (PID). In women with coexisting inflammatory diseases of the uterus, such as endometritis or PID, the diagnosis of adenomyosis may be particularly difficult. A combination of clinical, imaging, and histopathological findings is typically used to diagnose adenomyosis.

Clinical diagnosis of adenomyosis typically involves a detailed medical history and a physical examination. Women with adenomyosis may report heavy or prolonged menstrual bleeding, dysmenorrhea (painful periods), chronic pelvic pain, and dyspareunia (painful intercourse). Physical examination may reveal an enlarged, tender, and firm uterus. However, clinical diagnosis alone is not sufficient to confirm the diagnosis of adenomyosis.

Imaging studies, particularly transvaginal ultrasound (TVUS), are commonly used to diagnose adenomyosis. TVUS can visualize the thickening and irregularity of the myometrium and the presence of small cysts within the myometrium, known as adenomyomas. MRI can also be used to diagnose adenomyosis and may be more sensitive than TVUS in detecting adenomyotic lesions within the myometrium.

Histopathological examination of the uterine tissue is considered the gold standard for the diagnosis of adenomyosis. Endometrial biopsy or hysteroscopy can be used to obtain a sample of the endometrial tissue, while uterine biopsy or hysterectomy can be used to obtain a sample of the myometrial tissue.

Histopathological examination can confirm the presence of endometrial tissue within the myometrium and can rule out other conditions such as uterine fibroids or endometrial cancer.

In women with coexisting inflammatory diseases of the uterus, the diagnosis of adenomyosis may be more difficult due to the similar clinical presentation of these conditions. In these cases, a combination of clinical, imaging, and histopathological findings is essential to accurately diagnose adenomyosis and rule out other conditions.

The diagnosis of adenomyosis typically involves a combination of clinical, imaging, and histopathological findings. Imaging studies such as TVUS and MRI can visualize the thickening and irregularity of the myometrium, while histopathological examination is considered the gold standard for the diagnosis of adenomyosis. Accurate diagnosis of adenomyosis is essential to ensure appropriate management and to rule out other gynecologic conditions with similar clinical presentations.

TREATMENT

The treatment of adenomyosis can be challenging, as there is no definitive cure for the condition. Treatment options are aimed at managing the symptoms and improving the quality of life of women with adenomyosis. The choice of treatment depends on several factors, including the severity of symptoms, the age and reproductive status of the woman, and the presence of coexisting gynecologic conditions.

Medical management of adenomyosis typically involves the use of nonsteroidal anti-inflammatory drugs (NSAIDs) or hormonal therapies. NSAIDs such as ibuprofen or naproxen can help alleviate the pain and heavy bleeding associated with adenomyosis. Hormonal therapies such as oral contraceptives, progestins, gonadotropin-releasing hormone (GnRH) agonists, or danazol can also be used to manage the symptoms of adenomyosis. These hormonal therapies work by suppressing ovulation and reducing the production of estrogen, which can help shrink the adenomyotic lesions and improve symptoms. However, hormonal therapies are not suitable for all women, particularly those who are trying to conceive.

Surgical management of adenomyosis may be necessary in cases of severe or refractory symptoms. The surgical options for adenomyosis include hysterectomy,

myomectomy, endometrial ablation, and uterine artery embolization (UAE). Hysterectomy, or the removal of the uterus, is considered the definitive cure for adenomyosis, but is only appropriate for women who have completed their childbearing. Myomectomy, or the removal of the adenomyotic lesions, can also be performed, but is associated with a higher risk of recurrence than hysterectomy. Endometrial ablation involves the destruction or removal of the endometrial tissue, and can be performed using a variety of methods, including radiofrequency, thermal balloon, or cryoablation. UAE involves the injection of embolic agents into the uterine arteries to block blood flow to the adenomyotic lesions, leading to their shrinkage. UAE is a less invasive alternative to surgery, but is associated with a risk of complications such as pelvic pain or infection.

In women with coexisting inflammatory diseases of the uterus, the treatment of adenomyosis may be more challenging. In these cases, the underlying inflammatory condition must be treated first, followed by the management of adenomyosis.

The treatment of adenomyosis depends on several factors, including the severity of symptoms, the age and reproductive status of the woman, and the presence of coexisting gynecologic conditions. Medical management with NSAIDs or hormonal therapies can help alleviate symptoms, while surgical options such as hysterectomy, myomectomy, endometrial ablation, or UAE may be necessary in cases of severe or refractory symptoms. Accurate diagnosis and appropriate treatment of adenomyosis is essential to improve the quality of life of women with this condition.

CONCLUSION

Adenomyosis is a common gynecologic condition that can cause significant morbidity in women. The coexistence of inflammatory diseases of the uterus can complicate the diagnosis and management of adenomyosis. The pathophysiology of adenomyosis involves the invasion of endometrial tissue into the myometrium, resulting in the formation of adenomyotic lesions. The clinical features of adenomyosis are characterized by heavy menstrual bleeding, dysmenorrhea, and chronic pelvic pain. The diagnosis of adenomyosis is challenging and requires a combination of clinical examination, imaging, and histopathological evaluation. The treatment of adenomyosis is aimed at managing symptoms and improving quality of life, and can include medical

management with NSAIDs or hormonal therapies, or surgical options such as hysterectomy, myomectomy, endometrial ablation, or UAE. The choice of treatment depends on several factors, including the severity of symptoms, the age and reproductive status of the woman, and the presence of coexisting gynecologic conditions.

REFERENCES

1. Levgur M, Abadi MA, Tucker A, et al. Adenomyosis: symptoms, histology, and pregnancy terminations. Obstet Gynecol. 2000;95(5):688-691.
2. Vercellini P, Viganò P, Somigliana E, et al. Adenomyosis: epidemiological factors. Best Pract Res Clin Obstet Gynaecol. 2006;20(4):465-477.
3. Struble J, Reid S, Bedaiwy MA. Adenomyosis: a clinical review of a challenging gynecologic condition. J Minim Invasive Gynecol. 2016;23(2):164-185.
4. Johnson NP, Hummelshoj L. Consensus on current management of endometriosis. Hum Reprod. 2013;28(6):1552-1568.
5. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 128: Diagnosis of Abnormal Uterine Bleeding in Reproductive-Aged Women. Obstet Gynecol. 2012;120(1):197-206.
6. Stewart EA. Uterine fibroids. Lancet. 2001;357(9252):293-298.
7. Singh SS, Suen MW. Treatment of adenomyosis-associated menorrhagia with the levonorgestrel intrauterine system. Obstet Gynecol. 2008;111(1):22-28.
8. Campo S, Campo V, Benagiano G. Adenomyosis and infertility. J Am Assoc Gynecol Laparosc. 2004;11(2):227-229.
9. Benagiano G, Brosens I, Habiba M. Structural and molecular features of the endomyometrium in endometriosis and adenomyosis. Hum Reprod Update. 2014;20(3):386-402.
10. Osuga Y, Harada T, Takeda M, et al. Endometriosis-associated ovarian cancer: a review of

pathogenesis. Int J Mol Sci. 2020;21(11):3982.

11. Lasmar RB, Barrozo PR, Dias R, et al. Prevalence of adenomyosis in women undergoing surgery for endometriosis. Fertil Steril. 2007;87(6):1568-1572.

12. Sayed GH, Zakherah MS, El-Nashar SA, et al. Transvaginal ultrasonography and magnetic resonance imaging for diagnosis of adenomyosis. Fertil Steril. 2008;89(4): S245-S250.

13. Nisenblat V, Bossuyt PM, Farquhar C, et al. Imaging modalities for the non-invasive diagnosis of adenomyosis. Cochrane Database Syst Rev. 2016;(6):CD009458.

14. Eisenberg VH, Weil C, Chodick G, et al. Adenomyosis and the risk of preterm delivery. Eur J Obstet Gynecol Reprod Biol. 2013;171(2):214-218.

15. Santulli P, Borghese B, Chouzenoux S, et al. Endometriosis-related infertility: ovarian endometrioma per se is not associated with a poorer IVF outcome. Hum Reprod. 2016;31(09): 1913-1920.

16. Exacoustos C, Manganaro L, Zupi E. Imaging for the evaluation of endometriosis and adenomyosis. Best Pract Res Clin Obstet Gynaecol. 2014;28(5):655-681.

17. Benagiano G, Brosens I, Habiba M. Adenomyosis: a life-cycle approach. Reprod Biomed Online. 2015;30(3):220-232.

18. Li X, Li C, Liu C, et al. A systematic review and meta-analysis of the efficacy of medical treatments for adenomyosis. Gynecol Endocrinol. 2019;35(3):191-197.

19. Sizzi O, Cerqui E, Parodo G, et al. Laparoscopic myometrial electrocoagulation for the treatment of adenomyosis. Fertil Steril. 2000;74(4):643-646.

20. Falcone T, Bedaiwy MA. The efficacy of endometrial ablation for the treatment of adenomyosis-associated menorrhagia. Obstet Gynecol. 2002;100(4):748-751.